10results about How to "Induce apoptosis" patented technology

This invention discloses a multi-target synergistic anti-liver cancer medical food granule and its preparation method. The granule uses medicinal and edible homologous foods and novel resource foods as raw materials, and is composed of curcumin extract, esterified fat-soluble EGCG, Moringa leaf powder, yeast β-glucan, Astragalus extract, Schisandra extract, Salvia miltiorrhiza extract, Poria cocos powder, resistant dextrin, and erythritol in a specific ratio to construct a three-dimensional synergistic system of "direct killing-immune regulation-liver protection," which can induce ferroptosis in liver cancer cells, inhibit protective autophagy, activate the body's immunity, and protect liver cells. This invention employs directional extraction, multi-layer coating, and high-pressure fusion granulation technology. Nanoparticle liposome encapsulation, esterification modification, and pH-responsive enteric coating improve the stability and bioavailability of the components, solving the problems of poor water solubility, low absorption, and easy degradation of natural active ingredients. The granule has clear efficacy, high safety, and stable process, and can be used as a medical food for adjuvant therapy and nutritional support during the recovery period of liver cancer.

The invention discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors, belongs to the technical field of anti-tumor traditional Chinese medicines, and discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-25 parts of ginseng, 15-18 parts of selfheal, 12-18 parts of seaweed, 12-19 parts of astragalus membranaceus, 10-16 parts of angelica sinensis, 18-30 parts of oldenlandia diffusa, 10-15 parts of fleece-flower root, 10-14 parts of poria cocos, 10-16 parts of thunberg fritillary bulb, 8-14 parts of pseudobulbus cremastrae seu pleiones and 8-17 parts of curcuma zedoary. Through the specific pharmacological action, growth and proliferation of thyroid tumor cells are inhibited, the development speed of tumors can be slowed down, the malignancy degree of the tumors can be reduced, apoptosis of the thyroid tumor cells can be induced, and the number of the tumor cells can be effectively reduced by inducing apoptosis of the tumor cells, so that the anti-tumor purpose is achieved.

The invention belongs to the technical field of biological medicines, and particularly relates to a drug-loaded vesicle for treating thyroid cancer as well as a preparation method and application of the drug-loaded vesicle. The drug-loaded vesicle comprises a vesicle, wherein a cavity of the vesicle is loaded with radioactive iodine; the membrane surface of the vesicle is modified with: a) a first single-chain antibody fragment capable of specifically binding to thyroglobulin; according to the present invention, after the intravenous injection, the drug-loaded vesicle can be enriched in the thyroid cancer lesion area of the RAIR-DTC patient, such that the cancer cell proliferation is inhibited while the radioactive iodine is continuously released so as to provide the long-term treatment effect;

This invention discloses an acidic polysaccharide from Gynostemma pentaphyllum, AGPA12, its purification and extraction method, and its application in the preparation of anti-pancreatic cancer drugs. AGPA12 is mainly composed of mannose, glucuronic acid, rhamnose, glucose, galactose, and fucose, with a molar ratio of 1.05:1.74:6.29:1.40:69.48:19.03. The polysaccharide was extracted using an α-amylase-assisted water extraction and alcohol precipitation method, and purified by DEAE-Sepharose FF ion exchange chromatography and Sepharose CL6B gel chromatography. In vitro experiments showed that AGPA12 had significant inhibitory effects on the proliferation and migration of human pancreatic cancer AsPC1 cells, and its mechanism was related to the regulation of the MAPK signaling pathway and the expression of apoptosis-related proteins. This invention provides a new approach for the development of Gynostemma pentaphyllum polysaccharides and their application in anti-pancreatic cancer drugs.

This invention discloses a Sophora japonica polysaccharide HEP-3A, its preparation method, and its applications, belonging to the field of biomedicine. The invention obtains a novel acid-base amphoteric polysaccharide HEP-3A by defatting, hot water extraction, fractional alcohol precipitation, ion exchange, and gel column chromatography of Sophora japonica raw materials. Polysaccharide HEP-3A is composed of nine monosaccharides, with a well-defined structure and high purity; moreover, the preparation process is simple and controllable, with high yield, suitable for large-scale production. Experimental results show that polysaccharide HEP-3A can target and inhibit the binding of HIF-1α / β to CBP / p300, blocking the HIF-1 signaling pathway and inhibiting tumor angiogenesis, exhibiting broad-spectrum antitumor activity. In a liver cancer model, the tumor inhibition rate can reach 77.96%, and it has excellent safety, making it suitable for the preparation of antitumor drugs. This invention provides a new candidate compound for the development of new antitumor drugs.

This invention relates to an iron polyphenol nanocapsule, its preparation method, and its applications. The nanocapsule is prepared from raw materials containing ferric salts, ferric ions, and gossypol via a microfluidic chip. The iron polyphenol nanocapsule containing gossypol-ferric ions-ferric ions prepared by this invention using a microfluidic chip as a reactor exhibits uniform size and good stability. It can achieve co-delivery of dual chemotherapy drugs, T1 magnetic resonance imaging, and trimodal combined therapy of tumors (chemodynamic therapy / dual-channel chemotherapy / immunotherapy), showing potential applications in cancer diagnosis and treatment.

The present invention relates to compounds of general formula (i) in which r1, r2, r3, r4, l, x and z are as defined herein, and their pharmaceutically acceptable salts, pharmaceutical compositions comprising these compounds and salts, and methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

This invention belongs to the field of biomedical technology and discloses a recombinant adenovirus, its preparation method, and its applications. A recombinant adenovirus is disclosed, the genome of which contains a dual-gene expression cassette of a SOX7 gene and a KLF10 gene. The nucleotide sequence of the SOX7 gene is shown in SEQ ID NO. 1; the nucleotide sequence of the KLF10 gene is shown in SEQ ID NO. 2. Experimental results show that after transfecting tumor cells with this recombinant adenovirus in vitro, it can simultaneously and efficiently express SOX7 and KLF10 proteins, both maintaining normal transcriptional regulatory activity and without interference. Inoculation of tumor-bearing mice with this recombinant adenovirus can significantly inhibit tumor cell proliferation, induce apoptosis, and prolong the survival time of tumor-bearing mice, demonstrating broad application prospects.

The invention discloses a trabectedin-loaded nano-micelle and oxaliplatin-loaded drug combination composition and application, and relates to the technical field of delivery and drug combination, and the trabectedin-loaded nano-micelle and oxaliplatin-loaded drug combination composition comprises trabectedin-loaded nano-micelle and oxaliplatin. The invention also discloses an application of the combined pharmaceutical composition in preparation of antitumor drugs. According to the invention, a pH-sensitive amphiphilic biodegradable material (such as PCL-PEOz) and a chemical drug are self-assembled to form stable micelles, so that the bioavailability of the drug is improved, the critical concentration of the micelles is reduced, and long-acting circulation in vivo is realized; the system can be combined with oxaliplatin for use, so that the sensitivity of tumor cells to oxaliplatin is promoted, the synergistic effect of chemotherapy and immunotherapy is exerted, the treatment effect of malignant tumors is improved, and the tumor microenvironment is improved.

This invention discloses a composition for treating ABC type diffuse large B-cell lymphoma and its application, belonging to the field of biomedical technology. The composition comprises chidamide and psyllium phosphate. This invention constructs a synergistic therapeutic system of chidamide and psyllium phosphate, precisely overcoming the treatment challenges of ABC type diffuse large B-cell lymphoma. By targeting the dual key targets of HDAC3 and PIM1, this composition achieves synergistic effects of epigenetic regulation and signaling pathway inhibition, significantly improving anti-tumor efficacy. This invention successfully overcomes the bottleneck of poor efficacy and high relapse rate of existing R-CHOP regimens in the treatment of ABC subtype lymphoma, providing a novel, highly specific treatment strategy for relapsed or refractory ABC type diffuse large B-cell lymphoma, with broad clinical application prospects.